PTC Therapeutics Inc

2026-08-13 19:36; UTC

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

2026-08-12 23:51; UTC

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

2026-08-11 19:46; UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

2026-08-10 19:46; UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

2026-08-07 21:02; UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

2026-08-06 19:56; UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

2026-08-05 19:26; UTC

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

2026-08-04 20:07; UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

2026-08-03 19:46; UTC

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

2026-07-31 21:01; UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

2026-07-30 22:31; UTC

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

2026-07-29 18:26; UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

2026-07-28 18:31; UTC

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

2026-07-27 20:06; UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

2026-07-22 17:16; UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

2026-07-21 18:01; UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

2026-07-20 19:56; UTC

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.